HomeAI · summaries
Storia in 6 fonti
Servier signs $1.55B upfront deal for Edgewise's muscular dystrophy assets
Servier will pick up the muscular dystrophy business from Edgewise Therapeutics, giving the French pharma company access to an experimental neuromuscular medicine that could have pivotal data by year's end.
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
Servier buys into muscular dystrophy with potentially $2.7B deal
The French drugmaker has agreed to acquire an experimental tablet from Edgewise Therapeutics that some bullish analysts say could eventually hit peak sales of over $2 billion.
- ·
statnews.com
Servier to buy Edgewise Therapeutics' muscular dystrophy drug
The French pharma firm Servier is buying an experimental muscular dystrophy drug from Edgewise Therapeutics for $1.55 billion upfront.
